12:00 AM
 | 
Dec 24, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Ponesimod: Additional Phase IIb data

Additional data from a double-blind, international Phase IIb trial in 464 patients with RRMS showed that once-daily 10, 20 and 40 mg oral ponesimod for 24 weeks significantly reduced the cumulative number of new active inflammatory lesions as measured by monthly T1-weighted...

Read the full 189 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >